Cambridge Raman Imaging wins €400K EU grant, pivots to pharma quality control
Cambridge Raman Imaging (CRI) has secured a €400,000 European Innovation Council (EIC) Transition grant to scale its Raman imaging technology and AI. The non-dilutive funding comes from the European Union, portfolio company backer Frontier IP Group said on July 22, 2026.
CRI's technology analyses multiple Raman spectra at once to build a near real-time chemical picture of a compound, faster than systems that read one spectrum at a time. The grant will fund high-speed multimodal imaging for uses ranging from detecting cancerous tumours in human tissue to spotting microplastics in the environment.
The company is also broadening its focus to industrial quality control in pharmaceuticals — using the technology on production lines to check that tablets, pills, and powders contain the right amounts of active ingredients.
Regulatory barriers in industrial quality control are lower than in medical markets, giving CRI a faster path to scale. New rules such as Real-time Release Testing and Quality by Design are expected to drive demand. The company is in talks with two leading pharmaceutical groups to begin pilot testing.
The global market for pharmaceutical inspection equipment is valued at $5 billion and forecast to reach $13 billion by 2033.
Alongside the grant, CRI signed a distribution agreement with China's Hooke Instruments to enter the Chinese market for medical and scientific research microscopes. Hooke has more than 100 customers globally and will sell CRI's technology in China only.
At €400,000, the grant sits in the smaller tier of funding events tracked, but it is validation rather than dilution — Frontier IP retains a 26.81% stake in CRI. The award, distribution deal, and pharma pivot together mark CRI's shift from lab-stage promise toward commercial revenue.
Read more: Investegate
Image credit: Generated with Gemini
